Chemistry Professor Asel Sartbaeva said a vaccine against hantavirus could be available in three to five years [1].
The development of this vaccine is critical for public health preparedness, as hantavirus remains a significant threat that requires a targeted medical response.
Sartbaeva said the project is progressing and it is necessary to distinguish the virus from other respiratory illnesses. She said hantavirus is not COVID-19, aiming to prevent public panic while emphasizing the need for a preventative solution.
To bring the vaccine to market, Sartbaeva said she hopes to collaborate with pharmaceutical companies in India. Such partnerships would leverage regional manufacturing capabilities to accelerate the distribution of the vaccine once it clears testing phases.
The timeline for availability remains an estimate. Sartbaeva said the vaccine could be available in three to five years [1]. This window accounts for the rigorous testing, and regulatory approvals required for new vaccines.
While the research progresses, health officials continue to monitor hantavirus outbreaks. The focus of the current work is to create a stable and effective immunization that can be produced at scale through these potential industrial partnerships.
“Hantavirus vaccine could be available in three to five years”
The pursuit of a hantavirus vaccine represents a shift toward proactive prevention for zoonotic diseases. By seeking partnerships with Indian pharmaceutical firms, the research aims to bridge the gap between academic chemistry and mass-market production, potentially reducing the global vulnerability to hantavirus outbreaks.
